{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:22:46Z","timestamp":1793726566466,"version":"4.6.1"},"reference-count":46,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Successful management of onychomycosis is a challenge because cure rates with most antifungals are relatively low and recurrence rates are high. A drug\u2010based approach by treating the nail alone may not suffice. There are several host\u2010related factors (age, sex, body mass index [BMI], and patient\u2019s quality of life), disease\u2010related factors (disease severity, duration, and the number of toenails affected), and comorbidities (tinea pedis and diabetes) that may affect treatment efficacy. Here, we review the <jats:italic>post hoc<\/jats:italic> analyses of the phase III trials of efinaconazole 10% solution that have investigated the impact of these factors on topical therapy for toenail onychomycosis. The significant clinical variables that may affect the efficacy of efinaconazole include sex, BMI, disease severity, disease duration, and tinea pedis. As older patients may have slower toenail growth and more severe, longstanding disease compared with younger patients, they may require longer treatment duration, beyond the 48\u2010week standard regimen. Treatment compliance may need to be discussed for an improved health outcome. Therefore, these prognostic factors need to be carefully evaluated, which may aid in formulating individualized therapy to maximize treatment success.<\/jats:p>","DOI":"10.1111\/ijd.15739","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T07:59:18Z","timestamp":1625299158000},"page":"1296-1302","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["One size does not fit all: the need for individualized treatment based on factors that may affect the therapeutic outcome of efinaconazole 10% solution for the treatment of toenail onychomycosis"],"prefix":"10.1111","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Faculty of Medicine University of Toronto Toronto ON Canada"},{"name":"Mediprobe Research Inc London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maanasa","family":"Venkataraman","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Anbalagan","sequence":"additional","affiliation":[{"name":"Ortho\u2010Dermatologics Bridgewater NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Guenin","sequence":"additional","affiliation":[{"name":"Ortho\u2010Dermatologics Bridgewater NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417716362"},{"key":"e_1_2_8_3_1","unstructured":"Bausch Health Companies Inc.JUBLIA\u00ae(efinaconazole) topical solution[Internet]. Drugs@FDA.2020[cited 2021 Feb 17]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/203567s009lbl.pdf."},{"key":"e_1_2_8_4_1","unstructured":"Valeant Canada LP.PrJubliaTMEfinaconazole Topical Solution 10% w\/w Topical Antifungal Agent[Internet].2017[cited 2021 Feb 17]. Available from:https:\/\/pdf.hres.ca\/dpd_pm\/00040037.PDF."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.013"},{"key":"e_1_2_8_6_1","first-page":"815","article-title":"The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials","volume":"13","author":"Gupta AK","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_7_1","first-page":"286","article-title":"Efinaconazole solution 10% for treatment of toenail onychomycosis in Latino patients","volume":"99","author":"Cook\u2010Bolden FE","year":"2017","journal-title":"Cutis"},{"key":"e_1_2_8_8_1","first-page":"38","article-title":"Risk factors and comorbidities for onychomycosis: implications for treatment with topical therapy","volume":"8","author":"Elewski BE","year":"2015","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.7547\/14-088"},{"key":"e_1_2_8_10_1","first-page":"1186","article-title":"Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes","volume":"13","author":"Vlahovic TC","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_11_1","first-page":"58","article-title":"Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early","volume":"14","author":"Rich P","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_12_1","first-page":"42","article-title":"Onychomycosis of toenails and post\u2010hoc analyses with efinaconazole 10% solution once\u2010daily treatment: impact of disease severity and other concomitant associated factors on selection of therapy and therapeutic outcomes","volume":"9","author":"Del Rosso JQ","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_8_13_1","first-page":"24","article-title":"Efinaconazole topical solution, 10%, for the treatment of mild and moderate toenail onychomycosis","volume":"8","author":"Rodriguez DA","year":"2015","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_8_14_1","first-page":"197","article-title":"Evaluation of gender as a clinically relevant outcome variable in the treatment of onychomycosis with efinaconazole topical solution 10","volume":"96","author":"Rosen T","year":"2015","journal-title":"Cutis"},{"key":"e_1_2_8_15_1","first-page":"871","article-title":"Prognostic factors for complete cure following treatment of mild and moderate toenail onychomycosis with efinaconazole topical solution 10","volume":"14","author":"Jellinek NJ","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_16_1","first-page":"694","article-title":"Managing assessments and expectations: patient responses following therapy with efinaconazole topical solution, 10%","volume":"14","author":"Bhatia N","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000478664"},{"key":"e_1_2_8_18_1","first-page":"175","article-title":"Is severity of disease a prognostic factor for cure following treatment of onychomycosis?","volume":"17","author":"Elewski BE","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_19_1","first-page":"5","article-title":"Long\u2010term efficacy and safety of once\u2010daily efinaconazole 10% topical solution (Jublia) for dermatophyte toenail onychomycosis: an interim analysis","volume":"26","author":"Gupta AK","year":"2021","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.7547\/87507315-87-12-546"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.104794"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.11.3.415"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2000.00124.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02464.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200016060-00002"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962003000300006"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.8.2.240"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc12794"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2005.00165.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/NT.0000000000000092"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.10.1279"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/107110070502600506"},{"key":"e_1_2_8_33_1","first-page":"379","article-title":"The prevalence and management of onychomycosis in diabetic patients","volume":"10","author":"Gupta AK","year":"2000","journal-title":"Eur J Dermatol"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000514361"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000485632"},{"key":"e_1_2_8_36_1","first-page":"25","article-title":"Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life","volume":"7","author":"Tosti A","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-014-0096-2"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.010"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.109068"},{"key":"e_1_2_8_40_1","unstructured":"Health C for D and R.Medical Devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally\u2010Infected Nails.U.S. Food and Drug Administration;2019. Available from:https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/medical\u2010devices\u2010and\u2010clinical\u2010trial\u2010design\u2010treatment\u2010or\u2010improvement\u2010appearance\u2010fungally\u2010infected."},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof4030087"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119323396"},{"key":"e_1_2_8_43_1","unstructured":"Fungal Nail Infections | Fungal Diseases | CDC[Internet].2020[cited 2021 Feb 17]. Available from:https:\/\/www.cdc.gov\/fungal\/nail\u2010infections.html."},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpm.2019.12.015"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14935"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239648"},{"key":"e_1_2_8_47_1","first-page":"1260","article-title":"Topical treatment of onychomycosis and clinically meaningful outcomes","volume":"15","author":"Gupta AK","year":"2016","journal-title":"J Drugs Dermatol"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15739","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.15739","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:28:15Z","timestamp":1693294095000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.15739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/ijd.15739"],"URL":"https:\/\/doi.org\/10.1111\/ijd.15739","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,3]]},"assertion":[{"value":"2021-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}